Previous 10 | Next 10 |
Tenaya Therapeutics ( NASDAQ: TNYA ) said on Wednesday it will offer and sell $75M shares of common stock in an underwritten public offering. Tenaya intends to grant the underwriters a 30-day option to purchase up to an additional $11.25M of shares of its common stock at t...
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced...
Penny Stocks To Buy According To 5 Wall Street Analysts Today we look at a handful of penny stocks to buy, according to Wall Street analysts. It’s an interesting phenomenon when traders use ratings as part of their research methodologies. Sure, the so-called “smart mon...
Tenaya Therapeutics press release ( NASDAQ: TNYA ): Q3 GAAP EPS of -$0.74 misses by $0.11 . As of September 30, 2022, cash, cash equivalents and investments in marketable securities were $149.5M. Through prioritization of certain R&D and manufacturing expenditu...
Extends Cash Runway to Mid-2024 Commenced Dosing in Phase 1 Clinical Trial of TN-301; Data Expected in 2023 Plans to Submit TN-201 IND by Year End SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-st...
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced today that t...
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced today...
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced toda...
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced toda...
The following slide deck was published by Tenaya Therapeutics, Inc. in conjunction with this event. For further details see: Tenaya Therapeutics (TNYA) presents at H.C. Wainwright 24th Annual Global Investment Conference - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Tenaya Therapeutics Inc. Company Name:
TNYA Stock Symbol:
NASDAQ Market:
Tenaya Therapeutics Inc. Website:
Kathy Ivey, Ph.D., Promoted to Senior Vice President, Research and Timothy Hoey, Ph.D., Transitions to Advisory Role Pediatric Cardiologist and Genetic Therapy Expert Barry J. Byrne, M.D., Ph.D., Joins Scientific Advisory Board Board Member Jin-Long Chen, Ph.D., Steps Down ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that ...
2024-06-10 07:30:04 ET William Blair analyst issues OUTPERFORM recommendation for TNYA on June 10, 2024 05:41AM ET. TNYA was trading at $3.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recomm...